FDA Approves Brain Tumor Drug Targeting New Mutation

Rare and Aggressive Brain Cancer Affecting Children Gets Its First FDA-Approved Drug

Jazz Pharmaceuticals’ dordaviprone, brand name Modeyso, is now the first FDA-approved therapy for recurrent H3 K27M-mutant diffuse midline glioma. The drug came from Jazz’s $935 million acquisition of Chimerix earlier this year. The post Rare and Aggressive Brain Cancer Affecting Children Gets Its First FDA-Approved Drug appeared first on MedCity News.

Jazz gets FDA okay for Chimerix brain cancer drug

Jazz Pharmaceuticals has become the first drugmaker to get FDA approval for a treatment for diffuse midline glioma with H3 K27M mutations.

What is glioma? Symptoms explained after death of young actress

FDA Approves Brain Tumor Drug Targeting New Mutation

(MedPage Today) -- The FDA granted accelerated approval to dordaviprone (Modeyso) as the first systemic therapy for adults and children with diffuse midline glioma harboring H3 K27M mutations. Labeling stipulates use in individuals 1 year and...

US FDA Approves Jazz Pharma's Drug for Rare Brain Tumor